{"prompt": "['2016N277425_00', 'CONFIDENTIAL', '2018N377698_00', '201749', 'A description of the UMEC/VI investigational product administered via the ELLIPTAis', 'provided below in Table 1. The ELLIPTA will contain two, double-foil, laminate, blister', 'strips. The ELLIPTA will provide a total of 30 doses (60 blisters) and will deliver, when', 'actuated, the contents of a single blister simultaneously from each of the two blister', 'strips.', 'The DISKUS will provide a total of 60 doses and will deliver, when actuated, the', 'contents of a single blister.', 'A description of the UMEC investigational product administered via the ELLIPTA is', 'provided below in Table 2. A description of placebo inhalation powder via ELLIPTA is', 'shown in Table 3. A description of salmeterol 50mcg and placebo via DISKUS are', 'shown in Table 4 and Table 5 respectively.', 'Table 1', 'Description of UMEC/VI Inhalation Powder via ELLIPTA', 'Formulation', 'First strip', 'Second strip', 'Umeclidinium bromide blended with', 'Vilanterol trifenatate blended with', 'lactose monohydrate and', 'lactose monohydrate and magnesium', 'magnesium stearate1', 'stearate\u00b2', 'Dosage Form', 'ELLIPTA Inhaler with 30 doses (2 strips with 30 blisters per strip)', 'Unit Dose Strengths', '62.5 mcg', '25 mcg', 'Physical description', 'White powder', 'White powder', 'Route of Administration', 'Inhaled', '1.', 'Magnesium stearate 0.6% w/w of total drug product', '2.', 'Magnesium stearate 1.0% w/w of total drug product', 'Table 2', 'Description of UMEC Inhalation Powder via ELLIPTA', 'Formulation', 'First strip', 'Umeclidinium bromide blended with lactose', 'monohydrate and magnesium stearate1', 'Dosage Form', 'ELLIPTA Inhaler with 30 doses (1 strip with 30 blisters)', 'Unit Dose Strengths', '62.5mcg', 'Physical description', 'Dry white powder', 'Route of Administration', 'Inhaled', '1.', 'Magnesium stearate 0.6% w/w of total drug product', 'Table 3', 'Description of Placebo inhalation powder via ELLIPTA', 'Formulation', 'First strip', 'Second strip', 'Lactose monohydrate blended with', 'Lactose monohydrate blended with', 'magnesium stearate1', 'magnesium stearate\u00b2', 'Dosage Form', 'ELLIPTA Inhaler with 30 doses (2 strips with 30 blisters per strip)', 'Unit Dose Strengths', 'Not applicable', 'Not applicable', 'Physical description', 'Dry white powder', 'Dry white powder', 'Route of Administration', 'Inhaled', '1.', 'Magnesium stearate 0.6% w/w of total drug product', '2.', 'Magnesium stearate 1% w/w of total drug product', '35']['2016N277425_00', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Table 4', 'Description of salmeterol Inhalation powder via DISKUS', 'Formulation', 'First strip', 'Salmeterol Xinafoate blended with', 'lactose monohydrate', 'Dosage Form', 'Diskus Inhaler with 60 doses (1 strip', 'with 60 blisters per strip)', 'Unit Dose Strengths', '50 mcg', 'Physical description', 'White powder', 'Route of Administration', 'Inhaled', 'Table 5', 'Description of Placebo inhalation powder via DISKUS', 'Formulation', 'Lactose monohydrate', 'Dosage Form', 'Diskus Inhaler with 60 doses (1 strip', 'with 60 blisters per strip)', 'Unit Dose Strengths', 'Not Applicable', 'Physical description', 'White powder', 'Route of Administration', 'Inhaled', 'Albuterol/salbutamol via metered-dose-inhaler (MDI) will be issued for reversibility', 'testing at Visit 1. Albuterol/salbutamol MDI for as needed (prn) use will be issued', 'throughout the study. Albuterol/salbutamo will be sourced from local commercial stock', 'if appropriate.', '6.2.', 'Medical Devices', 'The eMDI devices are provided by GSK and are used in this study to electronically', 'record rescue medication usage. They have US FDA 510(K) clearance to market (Class', 'II device) and EU CE marking (Class I device). Description of the eMDI and its use will', 'be provided in the SRM.', '6.3.', 'Treatment Assignment', 'Subjects who meet the randomization criteria will be assigned to one of the 3 study', 'treatments in accordance with the randomization schedule generated by Clinical', 'Statistics, prior to the start of the study, using validated internal software.', 'Once a randomization number is assigned to a subject, it cannot be reassigned to any', 'other subject in the study.', 'This study will utilize RAMOS NG, which will provide a means for central allocation of', 'drug. Each investigator will be supplied with sufficient supplies to conduct the trial.', 'Additional treatment packs will be supplied as needed to the sites. Details of how to use', 'the RAMOS NG to randomize subjects is provided in the SRM.', 'The duration of treatment for each subject is 24 weeks. On the morning of each clinic', 'study visit, subjects will refrain from taking their morning dose of study treatment until', '36']\n\n###\n\n", "completion": "END"}